PRTK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 rugs. 2023 @ 23:00):

Stats
Šios dienos apimtis	4.48M
Vidutinė apimtis	599 679
Rinkos kapitalizacija	127.83M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $0 ) 2024-05-07
Last Dividend	$0.667 ( 2014-10-31 )
Next Dividend	$0 ( N/A )
P/E	-2.01
ATR14	$0.0250 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-21	Baylor-henry Minnie	Sell	32 800	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	26 400	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	12 800	Stock option (right to buy)
2023-09-21	Hoffmann Rolf K	Sell	64 000	Common Stock
2023-09-21	Hoffmann Rolf K	Sell	20 000	Common Stock

INSIDER POWER
-64.23
Last 96 transactions
Buy: 1 606 755 \| Sell: 5 363 965

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: 0.00 (neutral)

Signal:(59.187) Neutral

Paratek Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PAIC	0.948
SVOK	0.947
BIOL	0.912
RMRM	0.909
YMAB	0.899
SVAC	0.89
AVCT	0.883
TSP	0.879
UK	0.876
GAINL	0.876

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.954
NETE	-0.938
MMAC	-0.912
RAVN	-0.903
SHSP	-0.9
LMRK	-0.894
QADA	-0.878
VLYPO	-0.862
AMRB	-0.862
PODD	-0.858

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Paratek Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.48
( neutral )

0.40
( neutral )

0.00
( neutral )

0.53
( weak )

0.32
( neutral )

-0.23
( neutral )

Paratek Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$150.79M
Bruto pelnas:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2022
Pajamos:	$150.79M
Bruto pelnas:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2021
Pajamos:	$130.16M
Bruto pelnas:	$108.63M (83.46 %)
EPS:	$-1.201

FY	2020
Pajamos:	$46.92M
Bruto pelnas:	$38.27M (81.56 %)
EPS:	$-2.19

Financial Reports:

No articles found.

Paratek Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Paratek Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.312 - low (50.00%) | Divividend Growth Potential Score: 0.170 - No dividend growth expected in the near future

Information

First Dividend	$15.96	2014-05-21
Last Dividend	$0.667	2014-10-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	$40.59	--
Avg. Dividend % Per Year	0.00%	--
Score	1.91	--
Div. Sustainability Score	0.312
Div.Growth Potential Score	0.170
Div. Directional Score	0.241	--

Next Divdend (Est)
(2024-10-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.91

Pay Frequency

Bi-Monthly

Yearly Payout

Year	Amount	Yield
2014	$40.59	172.60%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.299	1.500	-5.98	-8.98	[0 - 0.5]
returnOnAssetsTTM	-0.287	1.200	-9.57	-10.00	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.63	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.519	0.800	-2.40	-1.923	[1 - 3]
quickRatioTTM	0.420	0.800	-2.23	-1.786	[0.8 - 2.5]
cashRatioTTM	0.211	1.500	9.94	10.00	[0.2 - 2]
debtRatioTTM	1.782	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-1.959	1.000	-1.837	-1.837	[3 - 30]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0949	-0.190	[0 - 20]
debtEquityRatioTTM	-1.290	-1.500	-5.16	7.74	[0 - 2.5]
grossProfitMarginTTM	0.850	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.201	1.000	-6.01	-6.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0416	1.000	-1.342	-1.342	[0.2 - 2]
assetTurnoverTTM	0.960	0.800	6.94	5.55	[0.5 - 2]
Total Score				0.312

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.05	1.000	-0.409	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.12	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0632	-0.190	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.179	1.500	-2.14	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0772	1.000	-4.43	0	[0.1 - 0.5]
Total Score				0.170

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.